Matthew Dennis

Neurogene has paused enrolment in the high-dose cohort of its gene therapy candidate NGN-401 for Rett syndrome as a patient who suffered a serious adverse event (AE) is now in a "critical condition."

Novo Nordisk's weight-loss treatment Wegovy (semaglutide) launched in China, with the GLP-1 receptor agonist priced significantly lower than in the US.

Having surprised investors by disclosing in September that a Phase III study of dapirolizumab pegol in moderate-to-severe systemic lupus

Merck & Co. said Tuesday that a subcutaneous formulation of Keytruda (pembrolizumab) was non-inferior to the currently-approved intravenous version

Pfizer will work with two more of Flagship Pioneering's portfolio companies, this time to develop drugs for obesity and non–small-cell lung cancer, as

Pfizer on Wednesday named Chris Boshoff as chief scientific officer and president of R&D, replacing the departing Mikael Dolsten effective January 1.

The European Commission approved Pfizer's Hympavzi (marstacimab) for the treatment of adults and adolescents with severe haemophilia A or B without inhibitors, the company said Wednesday.

Novartis is betting that new treatments for cancer and immunological diseases will drive growth in the medium term above previously expected levels.

Making good on comments made at its meet the management event around "value-creating bolt-ons," Novartis announced Thursday the acquisition of Kate

Neurogene disclosed in a filing with the US Securities and Exchange Commission that a patient who suffered a serious adverse event (AE) in an ongoing Phase I/II study of its gene therapy for Rett syndrome has now died.